Our new prognostic profile could allow clinicians to select sarcoma patients for adjuvant treatment or a more aggressive treatment strategy, and the presence of serum macrophage markers could serve as serum biomarkers for CD47 inhibitor immunotherapy in sarcoma. The gene discussed is CD47; the disease is sarcoma.